Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
14.86(c) 18.5(c) 21(c) 20.15(c) 19.4 Last
185 087 636 478 999 345 225 056 178 240 Volume
-0.40% +24.50% +13.51% -4.05% -3.72% Change
More quotes
Financials
Sales 2020 49,3 M 52,4 M 52,4 M
Net income 2020 -16,2 M -17,2 M -17,2 M
Net cash position 2020 88,0 M 93,4 M 93,4 M
P/E ratio 2020 -37,8x
Yield 2020 -
Sales 2021 69,3 M 73,5 M 73,5 M
Net income 2021 4,97 M 5,27 M 5,27 M
Net cash position 2021 10,9 M 11,6 M 11,6 M
P/E ratio 2021 -178x
Yield 2021 -
Capitalization 551 M 586 M 585 M
EV / Sales 2020 9,39x
EV / Sales 2021 7,79x
Nbr of Employees 135
Free-Float 105%
More Financials
Company
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
07/09MOLECULAR PARTNERS : to Collaborate with AGC Biologics for Manufacturing of Anti..
PU
07/07MOLECULAR PARTNERS AG : Molecular Partners Successfully Completes the Launch of ..
EQ
07/06MOLECULAR PARTNERS : successfully completes Private Placement of 5,528,089 Share..
PU
07/06MOLECULAR PARTNERS : announces the launch of a Private Placement of Shares by wa..
PU
06/29Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response..
AQ
06/26MOLECULAR PARTNERS : FDA Rejects Abicipar Pegol Application from Allergan, Molec..
DJ
05/15MOLECULAR PARTNERS : to Present Preclinical Data from MP0317, AMG 506 / MP0310 a..
PU
05/07INTERIM MANAGEMENT STATEMENT Q1 2020 : Continued progress on Abicipar, sharpened..
PU
04/29MOLECULAR PARTNERS : Shareholders of Molecular Partners AG Approve all Board Pro..
PU
04/19MOLECULAR PARTNERS : Initiates Anti-COVID-19 Therapeutic Program Leveraging Mult..
EQ
03/25MOLECULAR PARTNERS : Publishes Invitation to Annual General Meeting 2020
PU
03/20MOLECULAR PARTNERS : Publishes Audited Financial Results for 2019 and Annual Rep..
PU
02/24MOLECULAR PARTNERS : to Present at Two Upcoming Healthcare Investor Conferences
PU
02/20MOLECULAR PARTNERS : Announces Newly Nominated Board Members for Upcoming Annual..
PU
02/06MOLECULAR PARTNERS : reports key financials for FY 2019 and corporate highlights..
PU
More news
News in other languages on MOLECULAR PARTNERS AG
07/10Morning Briefing - Markt Schweiz
07/09Aktien Schweiz Schluss: US-Ausverkauf setzt dem SMI zu
07/09Bourse Zurich: les indices terminent en roue libre dans le rouge
07/09Molecular Partners sous-traite la production de son anti-covid-19 expérimenta..
07/09Molecular Partners arbeitet mit AGC Biologics bei Covid-19-Programm zusammen
More news
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 13,50 CHF
Last Close Price 20,15 CHF
Spread / Highest target -0,74%
Spread / Average Target -33,0%
Spread / Lowest Target -70,2%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Michael Tobias Stumpp Chief Operating Officer
Andreas Emmenegger Chief Financial Officer
Daniel Steiner Senior Vice President-Research
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG15.01%586
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955